ClinicalTrials.Veeva

Menu

Molecular Characterization of Gliomas Using a Broad Next Generation Sequencing (NGS)Panel

H

Hellenic Cooperative Oncology Group

Status

Completed

Conditions

Malignant Glioma

Study type

Observational

Funder types

Other

Identifiers

NCT05486247
NGSGLIOMA

Details and patient eligibility

About

Gliomas are the most common malignant primary brain tumors with poor prognosis. The genotyping of tumors using NGS platforms enables the identification of genetic alterations that constitute diagnostic, prognostic and predictive biomarkers.Here in, we investigated the molecular profile of 32 tumor samples from 32 patients with high grade gliomas by implementing a broad 80-gene targeted NGS panel while reporting their clinicopathological characteristics and outcomes.

Enrollment

32 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Diagnosis of high grade glioma based on tissue biopsy

Exclusion Criteria:

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems